Both monotherapy NPs and Dual-delivery systems, such as temozolomide co-delivered with MGMT-targeting siRNA, have consistently outperformed conventional therapies, significantly reducing tumor burden and extending survival in animal models. The gene discussed is MGMT; the disease is neoplasm.